Obstetrics & Gynaecology, Queen Charlotte's & Chelsea Hospital, Imperial College Healthcare NHS Trust, London, UK.
Addenbrooke's Hospital, Cambridge, UK.
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.
This is an update of the Cochrane review published in Issue 5, 2011. Worldwide, cervical cancer is the fourth commonest cancer affecting women. High-risk human papillomavirus (HPV) infection is causative in 99.7% of cases. Other risk factors include smoking, multiple sexual partners, the presence of other sexually transmitted diseases and immunosuppression. Primary prevention strategies for cervical cancer focus on reducing HPV infection via vaccination and data suggest that this has the potential to prevent nearly 90% of cases in those vaccinated prior to HPV exposure. However, not all countries can afford vaccination programmes and, worryingly, uptake in many countries has been extremely poor. Secondary prevention, through screening programmes, will remain critical to reducing cervical cancer, especially in unvaccinated women or those vaccinated later in adolescence. This includes screening for the detection of pre-cancerous cells, as well as high-risk HPV. In the UK, since the introduction of the Cervical Screening Programme in 1988, the associated mortality rate from cervical cancer has fallen. However, worldwide, there is great variation between countries in both coverage and uptake of screening. In some countries, national screening programmes are available whereas in others, screening is provided on an opportunistic basis. Additionally, there are differences within countries in uptake dependent on ethnic origin, age, education and socioeconomic status. Thus, understanding and incorporating these factors in screening programmes can increase the uptake of screening. This, together with vaccination, can lead to cervical cancer becoming a rare disease.
To assess the effectiveness of interventions aimed at women, to increase the uptake, including informed uptake, of cervical screening.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Issue 6, 2020. MEDLINE, Embase and LILACS databases up to June 2020. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies and contacted experts in the field.
Randomised controlled trials (RCTs) of interventions to increase uptake/informed uptake of cervical screening.
Two review authors independently extracted data and assessed risk of bias. Where possible, the data were synthesised in a meta-analysis using standard Cochrane methodology.
Comprehensive literature searches identified 2597 records; of these, 70 met our inclusion criteria, of which 69 trials (257,899 participants) were entered into a meta-analysis. The studies assessed the effectiveness of invitational and educational interventions, lay health worker involvement, counselling and risk factor assessment. Clinical and statistical heterogeneity between trials limited statistical pooling of data. Overall, there was moderate-certainty evidence to suggest that invitations appear to be an effective method of increasing uptake compared to control (risk ratio (RR) 1.71, 95% confidence interval (CI) 1.49 to 1.96; 141,391 participants; 24 studies). Additional analyses, ranging from low to moderate-certainty evidence, suggested that invitations that were personalised, i.e. personal invitation, GP invitation letter or letter with a fixed appointment, appeared to be more successful. More specifically, there was very low-certainty evidence to support the use of GP invitation letters as compared to other authority sources' invitation letters within two RCTs, one RCT assessing 86 participants (RR 1.69 95% CI 0.75 to 3.82) and another, showing a modest benefit, included over 4000 participants (RR 1.13, 95 % CI 1.05 to 1.21). Low-certainty evidence favoured personalised invitations (telephone call, face-to-face or targeted letters) as compared to standard invitation letters (RR 1.32, 95 % CI 1.11 to 1.21; 27,663 participants; 5 studies). There was moderate-certainty evidence to support a letter with a fixed appointment to attend, as compared to a letter with an open invitation to make an appointment (RR 1.61, 95 % CI 1.48 to 1.75; 5742 participants; 5 studies). Low-certainty evidence supported the use of educational materials (RR 1.35, 95% CI 1.18 to 1.54; 63,415 participants; 13 studies) and lay health worker involvement (RR 2.30, 95% CI 1.44 to 3.65; 4330 participants; 11 studies). Other less widely reported interventions included counselling, risk factor assessment, access to a health promotion nurse, photo comic book, intensive recruitment and message framing. It was difficult to deduce any meaningful conclusions from these interventions due to sparse data and low-certainty evidence. However, having access to a health promotion nurse and attempts at intensive recruitment may have increased uptake. One trial reported an economic outcome and randomised 3124 participants within a national screening programme to either receive the standard screening invitation, which would incur a fee, or an invitation offering screening free of charge. No difference in the uptake at 90 days was found (574/1562 intervention versus 612/1562 control, (RR 0.94, 95% CI: 0.86 to 1.03). The use of HPV self-testing as an alternative to conventional screening may also be effective at increasing uptake and this will be covered in a subsequent review. Secondary outcomes, including cost data, were incompletely documented. The majority of cluster-RCTs did not account for clustering or adequately report the number of clusters in the trial in order to estimate the design effect, so we did not selectively adjust the trials. It is unlikely that reporting of these trials would impact the overall conclusions and robustness of the results. Of the meta-analyses that could be performed, there was considerable statistical heterogeneity, and this should be borne in mind when interpreting these findings. Given this and the low to moderate evidence, further research may change these findings. The risk of bias in the majority of trials was unclear, and a number of trials suffered from methodological problems and inadequate reporting. We downgraded the certainty of evidence because of an unclear or high risk of bias with regards to allocation concealment, blinding, incomplete outcome data and other biases.
AUTHORS' CONCLUSIONS: There is moderate-certainty evidence to support the use of invitation letters to increase the uptake of cervical screening. Low-certainty evidence showed lay health worker involvement amongst ethnic minority populations may increase screening coverage, and there was also support for educational interventions, but it is unclear what format is most effective. The majority of the studies were from developed countries and so the relevance of low- and middle-income countries (LMICs), is unclear. Overall, the low-certainty evidence that was identified makes it difficult to infer as to which interventions were best, with exception of invitational interventions, where there appeared to be more reliable evidence.
这是 Cochrane 综述 2011 年第 5 期更新内容。在全球范围内,宫颈癌是女性第四大常见癌症。高危型人乳头瘤病毒(HPV)感染在 99.7%的病例中起致病作用。其他危险因素包括吸烟、多个性伴侣、存在其他性传播疾病和免疫抑制。宫颈癌的初级预防策略主要侧重于通过疫苗接种减少 HPV 感染,数据表明,这有潜力预防接种前接触 HPV 的人群中近 90%的病例。然而,并非所有国家都能负担得起疫苗接种计划,而且令人担忧的是,许多国家的疫苗接种率非常低。二级预防,通过筛查计划,仍将是减少宫颈癌的关键,特别是在未接种疫苗的妇女或在青春期后期接种疫苗的妇女中。这包括筛查癌前细胞以及高危型 HPV。在英国,自 1988 年引入宫颈癌筛查计划以来,宫颈癌相关死亡率有所下降。然而,在全球范围内,各国在覆盖率和参与率方面存在很大差异。在一些国家,有国家筛查计划,而在其他国家,筛查则是机会性的。此外,在参与率方面,存在因种族、年龄、教育和社会经济地位等因素而导致的差异。因此,在筛查计划中了解和纳入这些因素可以提高筛查的参与率。这与疫苗接种一起,可以使宫颈癌成为一种罕见疾病。
评估旨在提高女性宫颈癌筛查参与率的干预措施的有效性,包括知情参与率。
我们检索了 Cochrane 中心对照试验注册库(CENTRAL),2020 年第 6 期。MEDLINE、Embase 和 LILACS 数据库截至 2020 年 6 月。我们还检索了临床试验登记处、科学会议摘要、纳入研究的参考文献,并联系了该领域的专家。
旨在提高宫颈癌筛查参与率/知情参与率的干预措施的随机对照试验(RCT)。
两名综述作者独立提取数据并评估了偏倚风险。如果可能,我们使用标准 Cochrane 方法对数据进行了荟萃分析。
全面的文献检索确定了 2597 条记录;其中 70 项符合我们的纳入标准,其中 69 项试验(257899 名参与者)纳入荟萃分析。这些研究评估了邀请和教育干预、初级保健工作者参与、咨询和风险因素评估的有效性。由于试验之间存在临床和统计学异质性,因此无法对数据进行统计学汇总。总体而言,有中等确定性证据表明,与对照组相比,邀请似乎是一种有效的提高参与率的方法(RR 1.71,95%置信区间(CI)1.49 至 1.96;141391 名参与者;24 项研究)。进一步的分析,范围从低到中等确定性证据,表明个性化邀请,即个人邀请、全科医生邀请信或带有固定预约的信件,似乎更成功。更具体地说,有非常低确定性证据支持在两项 RCT 中使用全科医生邀请信而不是其他权威来源的邀请信,一项 RCT 评估了 86 名参与者(RR 1.69,95%CI 0.75 至 3.82),另一项 RCT 显示了适度的益处,包括超过 4000 名参与者(RR 1.13,95%CI 1.05 至 1.21)。低确定性证据支持个性化邀请(电话、面对面或有针对性的信件)而不是标准邀请信(RR 1.32,95%CI 1.11 至 1.21;27663 名参与者;5 项研究)。有中等确定性证据支持带有固定预约的信件,而不是带有开放式预约的信件(RR 1.61,95%CI 1.48 至 1.75;5742 名参与者;5 项研究)。低确定性证据支持教育材料的使用(RR 1.35,95%CI 1.18 至 1.54;63415 名参与者;13 项研究)和初级保健工作者的参与(RR 2.30,95%CI 1.44 至 3.65;4330 名参与者;11 项研究)。其他报道较少的干预措施包括咨询、风险因素评估、获得健康促进护士、漫画书、强化招募和信息框架。由于数据稀疏和低确定性证据,很难从这些干预措施中得出任何有意义的结论。然而,有机会获得健康促进护士和尝试密集招募可能会增加参与率。一项试验报告了一项经济结果,该试验在一项全国性筛查计划中随机分配了 3124 名参与者,要么接受标准筛查邀请,这将产生费用,要么接受免费的筛查邀请。在 90 天内没有发现参与率的差异(574/1562 干预组与 612/1562 对照组,(RR 0.94,95%CI:0.86 至 1.03)。HPV 自我检测作为替代传统筛查的方法也可能有效提高参与率,这将在随后的一篇综述中讨论。次要结局,包括成本数据,记录不完整。大多数集群 RCT 没有考虑到聚类或充分报告试验中的集群数量,以估计设计效果,因此我们没有选择性地调整这些试验。报告这些试验不太可能影响总体结论和结果的稳健性。在可以进行荟萃分析的分析中,存在相当大的统计学异质性,在解释这些发现时应考虑到这一点。鉴于此,以及低到中等的证据,进一步的研究可能会改变这些发现。大多数试验的偏倚风险不明确,并且一些试验存在方法学问题和不充分的报告。由于对分配隐藏、盲法、不完整的结局数据和其他偏倚存在不确定或高风险,我们降低了证据的确定性等级。
有中等确定性证据支持使用邀请信来提高宫颈癌筛查的参与率。低确定性证据表明,初级保健工作者的参与可能会增加少数民族人群的筛查覆盖率,但教育干预也有支持,但哪种干预形式最有效尚不清楚。大多数研究来自发达国家,因此,在中低收入国家(LMICs)的相关性尚不清楚。总体而言,由于存在低确定性证据,很难推断出哪种干预措施效果最好,除了邀请干预措施外,这些措施似乎有更可靠的证据。